Table 3 Baseline data of cataract patients reported in the FAERS database.
From: Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System
Variables | Data Presentation | Value |
|---|---|---|
Age (year) | Mean ± SD | 30.1 ± 12.9 |
Median (Q1, Q3) | 35 (19.41) | |
Weight (Kg) | Mean ± SD | 68.9 ± 25.3 |
Median (Q1, Q3) | 68 (54.85) | |
Gender | ||
Female | n (%) | 1351 (57.9%) |
Male | n (%) | 907 (33.3%) |
Unknown | n (%) | 77 (3.3%) |
Outcome | ||
Other serious condition | n (%) | 1617 (69.2%) |
Hospitalization- Initial or Prolonged | n (%) | 477 (20.4%) |
Disability | n (%) | 155 (6.6%) |
Life threatening condition | n (%) | 36 (1.5%) |
Required Intervention to Prevent | n (%) | 27 (1.2%) |
Death | n (%) | 24 (1.0%) |
Route | ||
Oral | n (%) | 697 (29.8%) |
Subcutaneous | n (%) | 322 (13.8%) |
Intravenous | n (%) | 161 (6.9%) |
Ophthalmic | n (%) | 91 (3.9%) |
Nasal | n (%) | 55 (2.4%) |
Respiratory (inhalation) | n (%) | 36 (1.5%) |
Intramuscular | n (%) | 34 (1.5%) |
Other administration | n (%) | 940 (40.2%) |
Country | ||
United States | n (%) | 776 (33.2%) |
Canada | n (%) | 193 (8.3%) |
Japan | n (%) | 111 (4.8%) |
United Kingdom | n (%) | 109 (4.7%) |
Germany | n (%) | 87 (3.7%) |
France | n (%) | 78 (3.3%) |
Brazil | n (%) | 69 (3.0%) |
India | n (%) | 48 (2.1%) |
Italy | n (%) | 44 (1.9%) |
China | n (%) | 37 (1.6%) |
Others | n (%) | 784 (33.6%) |
